Clinical trials: Thromboembolic Disorders
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- Trial name
- TALISCHER-SAH (NCT07821008)
- Testing
- Experimental group: ticagrelor
- Where
- 7 sites in France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Toulouse
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Venous Thromboembolism, Pulmonary Thromboembolisms
Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related.
- Conditions
- Venous Thromboembolism, Pulmonary Thromboembolisms, Cancer
- Trial name
- NCT03134820
- Volunteers
- 352 people
- Sponsor
- Delos Clinical
Thromboembolism, Hemodialysis
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
The purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.
- Trial name
- NCT00260988
- Testing
- Fragmin (dalteparin), Innohep (tinzaparin)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Thrombosis, Cancer
Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)
The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures.
- Conditions
- Thrombosis, Cancer, Thrombosis, Deep Vein, Atrial Fibrillation (AF)
- Trial name
- ACE-HIGH (NCT07372716)
- Testing
- standardized perioperative anticoagulation management Guideline
- Where
- Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Thrombotic Thrombocytopenic Purpura
Octaplas Adult TTP Trial
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in…
- Trial name
- NCT01938404
- Testing
- Octaplas, Standard Plasma
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Octapharma
Covid-19, Thromboembolic Events
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission…
- Conditions
- Covid-19, Thromboembolic Events, Bleeding
- Trial name
- NCT04412304
- Testing
- Dose of Tinzaparin or Dalteparin
- Where
- Sweden
- Volunteers
- 166 people
- Sponsor
- Karolinska Institutet
Chronic Thromboembolic Pulmonary Hypertension
Hemodynamic Effects of BPA at Rest and During Exercise in CTEPH
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by obstruction of the pulmonary vasculature by residual organized thrombi, leading to increased pulmonary vascular resistance (PVR), progressive pulmonary…
- Trial name
- EXPERT-BPA (NCT04052243)
- Testing
- Invasive exercise testing
- Where
- 3 sites in Denmark, Japan and 1 more
- Volunteers
- 80 people
- Sponsor
- Aarhus University Hospital
Atrial Fibrillation, Tachycardia
Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
This is an observational registry study aiming to collect data on efficacy and safety of the single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up period is 24 months.
- Conditions
- Atrial Fibrillation, Tachycardia, ICD Therapy, Thromboembolic Events
- Trial name
- MATRIX (NCT01774357)
- Where
- Germany
- Volunteers
- 2,054 people
- Sponsor
- Biotronik SE & Co. KG
Atrial Fibrillation, Anticoagulant-induced Bleeding
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.
- Trial name
- MAS (NCT03803579)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Arianna Anticoagulazione Foundation
Venous Thromboembolism
Follow-up in Rivaroxaban Patients in Setting of Thromboembolism
In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes.
- Trial name
- FIRST (NCT02248610)
- Testing
- Non-interventional study
- Where
- 4 sites in United Kingdom
- Volunteers
- 1,343 people
- Sponsor
- King's College Hospital NHS Trust
Thromboembolism
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks.
- Trial name
- EXTEND (NCT00206089)
- Testing
- EXANTA
- Where
- 125 sites in Austria, Belgium and 14 more
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Silent Cerebral Infarct, Biomarkers / Blood
Biomarkers as Prognostic Factors of Silent, Cerebral Infarctions in Patients Undergoing High-thromboembolic-risk Transcatheter Interventions
Background: The transcatheter interventions with high thromboembolic risk, as transcatheter carotid angioplasty or transcatheter ablation of cardiac arrhythmias are associated with asymptomatic strokes- silent strokes.
- Conditions
- Silent Cerebral Infarct, Biomarkers / Blood, Cardiac Ablation, Cognitive Impairment
- Trial name
- PRINCESS (NCT07844850)
- Testing
- High-thromboembolic-risk transcatheter interventions
- Where
- Greece
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Deep Venous Thrombosis, Pulmonary Embolism
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
- Trial name
- NCT04583878
- Testing
- Blood draw (Visit 1), Blood draw (Visits 2 and 3)
- Where
- 14 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Lung Neoplasms, Respiratory Failure
Clearance Of Mucus In Stents (COMIS)
The goal of this clinical research study is to compare the effects of sodium bicarbonate to normal saline when used for clearing mucus blockage in patients with airway stents.
- Conditions
- Lung Neoplasms, Respiratory Failure, Pneumonia, Acute Coronary Syndromes
- Trial name
- NCT01370278
- Testing
- Normal Saline, Sodium Bicarbonate
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism
Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005
The purpose of this study is to describe the incidence of thromboembolic events in relation to pregnancy and when in pregnancy and the puerperal period.
- Trial name
- NCT01176305
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hillerod Hospital, Denmark
Venous Thromboembolism
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
This study is a multicenter, double-blind, randomized, prospective phase 2 dose ranging study to evaluate the safety and efficacy of Dimolegin - DD217 in prevention of venous thromboembolic complications in patients underwent…
- Trial name
- NCT05189002
- Testing
- Dimolegin 40 mg, Dimolegin 60 mg, Fragmin
- Where
- 15 sites in Russia
- Volunteers
- 240 people
- Sponsor
- PharmaDiall Ltd.
Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary…
- Conditions
- Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07777445
- Testing
- 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Silvia Ulrich Somaini